For four decades, pancreatic cancer remained one of medicine's most merciless diseases — a diagnosis that seemed to end conversations rather than change them. When the cancer was discovered, it had almost always already spread beyond the pancreas, a stage called metastatic disease. Patients lived months, not years. The five-year survival rate hovered below 3%. Chemotherapy offered only modest extensions, measured in weeks or a few months at best. Immunotherapy, which had revolutionized treatment for other cancers, largely failed. The culprit was a mutated gene called KRAS, present in 90 to 95 percent of all pancreatic cancers. For generations, researchers called it "undruggable" — a molecular locked box they simply could not open.
That era appears to be ending. In June 2026, researchers presented results from a landmark clinical trial at the American Society of Clinical Oncology Annual Meeting that drew a rare standing ovation from the gathered oncologists. A new drug called daraxonrasib nearly doubled survival time for patients with metastatic pancreatic cancer, extending median survival to 13.2 months compared to 6.7 months with standard chemotherapy. In a disease measured by months, this represents a seismic shift — not an incremental improvement but a near-doubling of life expectancy in one of medicine's most lethal cancers.
The breakthrough hinges on a creative solution to an old problem. KRAS acts as a molecular on-switch for cancer cell growth. When mutation locks it in the "on" position, cancer cells proliferate without control. For 40 years, scientists failed to design drugs that could turn KRAS off directly — the protein lacked the structural features that targeted cancer drugs needed to bind to it. Daraxonrasib takes a different path. Instead of targeting KRAS directly in its active state, the drug traps the protein in an inactive form, preventing it from being turned on by the cell's normal signaling machinery. Because most pancreatic cancers carry the same KRAS mutation, daraxonrasib has the potential to help the vast majority of patients diagnosed with this disease going forward.
Dallas is positioned at the center of this revolution. UT Southwestern Medical Center, home to the Simmons Comprehensive Cancer Center — a nationally designated cancer center by the National Cancer Institute — has operated one of the world's most advanced KRAS research programs for years. Several of its oncology and biochemistry researchers contributed to the foundational science that made drugs like daraxonrasib possible. Dallas County sees more than 3,000 new pancreatic cancer diagnoses each year across the DFW metropolitan area. For patients at UT Southwestern, Baylor Scott & White, and Texas Health Resources currently undergoing treatment, or for families who learned a diagnosis only recently, these findings represent something that did not exist one year ago: genuine, evidence-backed hope.
Though daraxonrasib awaits full FDA approval, patients should ask their oncologists about clinical trial eligibility now. The National Cancer Institute's cancer trial finder lists open enrollment studies by diagnosis and location, offering potential access to the drug before broader availability. For a disease that has long offered little reason for optimism, that possibility itself marks a turning point.